Why do children fall ill
more severely than adults?
Immature immune processes pose a high risk of complications and a longer period of virus elimination1.
Low production of interferons, proteins actively combating the virus. The adult level is achieved by 12–18 years1.
Immune processes in the mucosae are immature, their protective properties are reduced1.
Intoxication symptoms (muscle pain, fever, shiver) are usually more pronounced than in adults.
Polyoxidonium®: combined action
for ARVI and influenza treatment
The drug can:
reduce the viral load2 due to the increase in own interferon production
alleviate the disease severity by reducing inflammation and intoxication3
prevent bacterial complications4
boost mucosae protective properties due to increased production of lysozyme5
Pharmaceutical form
Children aged 3 years and older
Schedule of administration of tablets 12 mg
for the treatment of acute respiratory infections
From 3 to 10 years
½ of a tablet
2 times a day sublingually
7 days course
From 10 years
1 tablet
2 times a day sublingually
7 days course
Children aged 6 years and older
Suppositories 6 mg
for the treatment of acute respiratory infections
From 6 years
1 suppository 6 mg
1 time a day
10 days course
Polyoxidonium® can take care of every child
The Polyoxidonium® action is well known: the properties of the drug have been confirmed by many studies, including the highest standard of evidence-based medicine — a meta-analysis of studies among children from 3 to 18 years old3
Compatible with many drugs5
Chemically pure drug, does not contain antigens of animal or plant origin. Suitable for children with allergic pathologies5
20-year experience in therapy and pediatrics
Polyoxidonium® does not cause hyperactivation of the immune system6
Polyoxidonium® for the prevention of viral infections
Polyoxidonium® can have prolonged preventive action:
- helps boost immunity5,
- activates factors of early protection from viral infections5,
- reduces ARVI and influenza reoccurrence7.
The major part of the children can be excluded from the group of frequently and chronically ill children after the treatment8.
Dosing schedule of Polyoxidonium® tablets 12 mg for the prevention of acute respiratory infections
Children aged 3–10 years
For the prevention of acute respiratory infections
½ of a tablet
1 time a day sublingually
7 days course
Children aged 10 years and older
For the prevention of acute respiratory infections
1 tablet
1 time a day sublingually
7 days course
In case of any drug-associated adverse events or any claims to the product quality, please contact NPO Petrovax Pharm, LLC:
by e-mail: ADR@petrovax.ru
Or use pharmacovigilance feedback page: http://petrovax.ru/medication/safety
- Yarilin, A.A. (2010). Immunology, Moscow, GEOTAR-Media, 752, 520.
- Isaeva, E.I., et al. (2019). Study of antiviral activity of Polyoxidonium on an experimental in vitro model. Journal of Infectology, vol. 11, No.1, app. 1, 5–13.
- Karaulov, A.V., Gorelov, A.V. (2019). The use of azoximer bromide for treatment of inflammatory infections of respiratory system in children: a meta-analysis of controlled clinical studies. Journal of Infectology, vol. 11, No. 4, 31–41.
- Morozova, S.V. (2010). The use of Polyoxidonium® immunocorrecting drug in acute infectious inflammatory pathology of ENT-organs. Russian Medical Journal, vol. 18, No. 24.
- Patient information leaflet for Polyoxidonium®.
- Letter of the Russian Association of Allergologists and Clinical Immunologists.
- Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.
- Mustafaev, D.M., Yegorov, V.I. (2016). Immunomodulatory therapy in ENT practice. Medical Council, No. 18.